Technology | March 12, 2012

Varian Receives FDA Clearance for Use of Transponder to Monitor Motion During Radiotherapy

March 12, 2012 — Varian Medical Systems received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for a surface beacon transponder to be used with the Calypso system as a tracking device capable of monitoring motion during radiotherapy treatments for indications anywhere in the body. The Surface Beacon Transponder is placed temporarily on the skin for real-time tracking of respiratory and other patient motion during radiotherapy, greatly expanding the number of cancer sites for which the Calypso technology can be used.

"Our new surface transponder allows users to track patient motion in real-time during treatment," said Chris Toth, vice president of marketing for Varian's Oncology Systems group. "It can be placed on a patient's chest wall to monitor respiratory motion during radiotherapy. It is designed to improve targeting in some of the most prevalent types of cancer, including breast cancer."

For example, chest wall monitoring during treatment of the left breast can correlate with the position of the heart. Having a tool to monitor this position in real time enables clinicians to design treatments that eliminate or significantly reduce dose to the heart. Breast cancer is the most common cancer for women in the United States — an estimated 30 percent of women will develop breast cancer over their lifetime.

Varian acquired Calypso in October 2011 to extend the company's range of real-time tracking tools aimed at enhancing the precision of radiotherapy treatments.

"These products are a perfect complement for Varian's motion management technology, including our TrueBeam platform and dynamic imaging tools for highly focused radiosurgery," says Tim Guertin, president and CEO of Varian Medical Systems. "Achieving 510(k) clearance for the Surface Beacon Transponder expands the range of applications for the Calypso 'GPS for the body' real-time tracking solution."

For more information: www.varian.com

Related Content

MERCK and RefleXion Medical announced a collaboration to evaluate KETRUDA (immunotherapy) with biology-guided radiotherapy - BgRT -  a new radiation machine developed to treat all stages of cancer.

MERCK and RefleXion Medical announced a collaboration to evaluate KETRUDA (immunotherapy) with biology-guided radiotherapy - BgRT -  a new radiation machine developed to treat all stages of cancer.

 

News | Radiation Therapy | June 01, 2020
June 1, 2020 — RefleXion Medical, a therape
Miami Cancer Institute’s Proton Therapy Center is the first in South Florida and the region’s top destination for this leading-edge treatment. Proton therapy is an advanced form of radiation therapy that uses pencil beam scanning (PBS) technology.

Miami Cancer Institute’s Proton Therapy Center is the first in South Florida and the region’s top destination for this leading-edge treatment. Proton therapy is an advanced form of radiation therapy that uses pencil beam scanning (PBS) technology.

Feature | Proton Therapy | May 27, 2020 | By Minesh Mehta, M.D.
Radiation therapy has advanced significantly in the last few decades as a result of a continued technological revolut
Technology becomes a state-of-the-art tool when it gets exposed to a structure that constantly tests it and allows it to evolve.

Technology becomes a state-of-the-art tool when it gets exposed to a structure that constantly tests it and allows it to evolve. Getty Images

Feature | Oncology Information Management Systems (OIMS) | May 27, 2020 | By Reshu Gupta
In the history of medicine, researchers have found cures for many diseases, but cancer has been elusive.
The global radiation therapy market is expected to reach $10.11 billion in 2024, witnessing growth at a CAGR of 3.38%, over the period 2020-2024.
News | Proton Therapy | May 20, 2020
May 20, 2020 — ResearchAndMarkets.com has released its latest report, the ...
An innovative radiation treatment that could one day be a valuable addition to conventional radiation therapy for inoperable brain and spinal tumors is a step closer, thanks to new research led by University of Saskatchewan (USask) researchers at the Canadian Light Source (CLS).

USask PhD bio-medical engineering student Farley Chicilo at the Canadian Light Source synchrotron at University of Saskatchewan. Photo courtesy of Canadian Light Source, University of Saskatchewan

News | Radiation Therapy | May 14, 2020
May 14, 2020 — An innovative radiation treatment t
Medical University of South Carolina researchers have developed and validated prediction tools, known as nomograms, that could be used to help prevent delays in the initiation of radiotherapy after surgery for head and neck cancer

 

Evan Graboyes, M.D., and his team believe their nomogram tools will improve survival rates for head and neck cancer patients. Photo courtesy of MUSC Hollings Cancer Center

 

News | Radiation Oncology | May 14, 2020
May 14, 2020 — More than 65,000 Americans are diagnosed annually with head and neck cancer, which most often occurs i
Due to ongoing health concerns related to the spread of the Coronavirus (COVID-19) as well as global travel restrictions, the American Association of Physicists in Medicine (AAPM) has decided to evolve the Joint AAPM/COMP (Canadian Organization of Medical Physicists) Meeting content into a virtual (completely online) meeting in place of the in-person meeting originally scheduled for July 12-16, 2020, in Vancouver, BC.
News | AAPM | May 11, 2020
May 11, 2020 — Due to ongoing health concerns related to the spread of the Coronavirus (...
Figure 1: CT image of lesions in different planes

Figure 1: CT image of lesions in different planes.

Sponsored Content | Case Study | Radiation Oncology | April 30, 2020 | By Christopher Bowen, M.S., DABR